Dyadic International (DYAI) Expected to Announce Quarterly Earnings on Wednesday

Dyadic International (NASDAQ:DYAI) is projected to announce its Q2 2025 earnings results after the market closes on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $0.60 million for the quarter.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.07) earnings per share for the quarter. The company had revenue of $0.39 million during the quarter. Dyadic International had a negative net margin of 163.94% and a negative return on equity of 233.69%. On average, analysts expect Dyadic International to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Dyadic International Stock Performance

Shares of DYAI stock opened at $0.94 on Monday. The company’s fifty day simple moving average is $0.99 and its 200-day simple moving average is $1.20. The company has a quick ratio of 3.98, a current ratio of 3.98 and a debt-to-equity ratio of 5.40. The firm has a market cap of $28.19 million, a PE ratio of -4.68 and a beta of 0.89. Dyadic International has a 12 month low of $0.91 and a 12 month high of $2.20.

Institutional Trading of Dyadic International

An institutional investor recently raised its position in Dyadic International stock. Bank of America Corp DE lifted its holdings in Dyadic International Inc. (NASDAQ:DYAI) by 16,146.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,132 shares of the biotechnology company’s stock after purchasing an additional 26,965 shares during the quarter. Bank of America Corp DE owned 0.09% of Dyadic International worth $47,000 as of its most recent SEC filing. 27.95% of the stock is currently owned by hedge funds and other institutional investors.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.